TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43 rd ...

The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs. That was certainly one of the ...

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing market share and reducing costs despite initial barriers. Despite rapid ...

Alvotech ( (ALVO) ) just unveiled an announcement.

A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, ...

The biosimilar will be available in subcutaneous and intravenous forms, with market entry anticipated in February 2025. Stelara's patent expiration has spurred biosimilar approvals, potentially ...

A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences ...

WASHINGTON, Dec. 17, 2024 /PRNewswire/ -- Biosimilars could lower the cost of treating cancer, autoimmune disorders and other serious conditions if policies allowed patients to access the medicati ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received a positive CHMP opinion for its filgrastim biosimilar, Zefylti, intended to treat neutropenia and mobilize peripheral progenitor cells.

Biologic medicines have transformed the treatment of numerous serious disorders. Biosimilars, offering comparable safety and efficacy at a fraction of the cost, have driven significant healthcare ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

The FDA has approved Celltrion’s Stelara biosimilar Steqeyma (CT-P43), for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults with Crohn’s disease and ...